Literature DB >> 31339226

Congenital spindle cell rhabdomyosarcoma.

Sarah B Whittle1,2, M John Hicks3, Angshumoy Roy3, Sanjeev A Vasudevan1,4, Kiranmye Reddy1,2, Rajkumar Venkatramani1,2.   

Abstract

Spindle cell and sclerosing rhabdomyosarcoma (ssRMS) is a rare variant of rhabdomyosarcoma, which includes three distinct subtypes. In infants, these tumors are commonly associated with recurring fusions involving VGLL2 or NCOA2 and have a favorable prognosis. We present four cases of ssRMS and 16 additional cases from the literature, which show that these patients present with localized disease and have an excellent prognosis regardless of surgical margin or lack of radiation therapy. Molecularly defined spindle cell rhabdomyosarcoma in infants is likely a biologically distinct entity which may not require the aggressive multimodal treatment used for other subtypes of rhabdomyosarcoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NCOA2; VGLL2; congenital; pediatric; rhabdomyosarcoma

Mesh:

Substances:

Year:  2019        PMID: 31339226     DOI: 10.1002/pbc.27935

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis.

Authors:  Sarah Whittle; Rajkumar Venkatramani; Anton Schönstein; Svetlana D Pack; Rita Alaggio; Christian Vokuhl; Erin R Rudzinski; Anna-Lena Wulf; Angelica Zin; Juliana R Gruver; Michael A Arnold; Johannes H M Merks; Simone Hettmer; Ewa Koscielniak; Frederic G Barr; Douglas S Hawkins; Gianni Bisogno; Monika Sparber-Sauer
Journal:  Eur J Cancer       Date:  2022-04-19       Impact factor: 10.002

Review 2.  Racial and ethnic disparities among children with primary central nervous system tumors in the US.

Authors:  Edwin Nieblas-Bedolla; Briana Christophers; John R Williams; Alexandra Power-Hays; Nathalia Jimenez; Analiz Rodriguez
Journal:  J Neurooncol       Date:  2021-03-28       Impact factor: 4.130

Review 3.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

4.  Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.

Authors:  Wenqing Qi; Wojciech Rosikiewicz; Zhaohong Yin; Beisi Xu; Huihong Jiang; Shibiao Wan; Yiping Fan; Gang Wu; Lu Wang
Journal:  J Pathol       Date:  2022-04-26       Impact factor: 9.883

5.  Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.

Authors:  Hannah D Rees; Nancy K Hills; Amit J Sabnis; Asmin B Tulpule; Tom K Shimotake; Robert E Goldsby
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.